| [1] | Akerele O (1993) In Summary of WHO guidelines for the assessment of herbal medicine. Herbalgram 28: 13–19.
|
| [2] | Potterat O, Hamburger M (2008) Drug discovery and development with plant-derived compounds. In: Petersen F, Amstutz R, editors. Progress in drug research: natural compounds as drugs. Birh？usser: Verlag AG. Pp. 45–118.
|
| [3] | Chin YW, Balunas MJ, Chai HB, Kinghorn AD (2006) Drug discovery from natural sources. The AAPS Journal 8(2): E239–E253.
|
| [4] | Li JWH, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161–165.
|
| [5] | Quinn RJ, Carroll AR, Pham MB, Baron P, Palframan ME, et al. (2008) Developing a drug-like natural product library. J Nat Prod 71: 464–468.
|
| [6] | Harvey AL (2008) Natural products in drug discovery. Drug Discov Today 13: 894–901.
|
| [7] | Newman DJ (2008) Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 51: 2589–2599.
|
| [8] | Efange SMN (2002) Natural products: a continuing source of inspiration for the medicinal chemist. In: Iwu MM, Wootton JC, editors. Advances in Phytomedicine. Amsterdam: Elsevier Science. 61–69.
|
| [9] | Grabowski K, Baringhaus KH, Schneider G (2008) Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep 25: 892–904.
|
| [10] | Grabowski K, Schneider G (2007) Properties and architecture of drugs and natural products revisited. Curr Chem Biol 1: 115–127.
|
| [11] | Wetzel S, Schuffenhauer A, Roggo S, Ertl P, Waldmann H (2007) Cheminformatic analysis of natural products and their chemical space. Chimia Int J Chem 61: 355–360.
|
| [12] | Hostettmann K, Marston A, Ndjoko K, Wolfender JL (2000) The potential of African plants as a source of drugs. Curr Org Chem 4: 973–1010.
|
| [13] | H？ltje HD, Sippl W, Rognan D, Folkers G (2008) Molecular modeling: basic principles and applications. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA. 181–258 p.
|
| [14] | Kubinyi H (1998) Combinatorial and computational approaches in structure-based drug design. Curr. Opin. Drug Discov Devel 1, 16–27.
|
| [15] | DiMasi JA, Hansen RW, Grabowsk HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151–185.
|
| [16] | Ntie-Kang F, Mbah JA, Mbaze LM, Lifongo LL, Scharfe M, et al. (2013) CamMedNP: Building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med 13: 88.
|
| [17] | Zofou D, Ntie-Kang F, Sippl W, Efange SMN (2013) Bioactive natural products derived from the Central African flora against Neglected Tropical Diseases and HIV. Nat Prod Rep 30: 1098–1120.
|
| [18] | Ntie-Kang F, Onguéné PA, Scharfe M, Owono LCO, Megnassan E, et al.. (2013) ConMedNP: An in silico assessment of the “druglikeness” and medicinal potential of a natural product library from medicinal plants in Central Africa. RSC Advances, submitted.
|
| [19] | Couzin J (1998) Supercomputing-computer experts urge new federal initiative. Science 281: 762.
|
| [20] | Irwin JJ, Shoichet BK (2005) ZINC – A free database of commercially available compounds for virtual screening. J Chem Inf Model 45(1): 177–182.
|
| [21] | Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG (2012) ZINC: A free tool to discover chemistry for biology. J Chem Inf Model 52: 1757–1768.
|
| [22] | Buzbee B (1993) Workstation clusters rise and shine. Science 261: 852–853.
|
| [23] | Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23: 3–25.
|
| [24] | Chapman and Hall/CRC Press: Dictionary of Natural Products on CD-Rom. London; 2005.
|
| [25] | ChemBridge Corporation website. Available: http://chembridge.com/Accessed 2013 June 13.
|
| [26] | Feher M, Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43: 218–227.
|
| [27] | Nkanwen ERS, Gojayev AS, Wabo HK, Bankeu JJK, Iqbal MC, et al. (2013) Lanostane-type triterpenoid and steroid from the stem bark of Klainedoxa gabonensis. Fitoterapia 86: 108–114.
|
| [28] | Mdee LK, Waibel R, Nkunya MHH, Jonker SA, Achenbach H (1998) Rosane diterpenes and bis-dinorditerpenes from Hugonia casteneifolia. Phytochemistry 49: 1107–1113.
|
| [29] | Sob SVT, Wabo HK, Tang C-P, Tane P, Ngadjui BT, et al. (2011) Phenol esters and other constituents from the stem barks of Stereospermum acuminatissimum. J Asian Nat Prod Res 13: 1128–1134.
|
| [30] | Schr？dinger Press: QikProp 3.4 User Manual, LLC, New York, NY, 2011.
|
| [31] | Teague SJ, Davis AM, Leeson PD, Opea TI (1999) The design of leadlike combinatorial libraries. Angew Chem, Int Ed 38: 3743–3748.
|
| [32] | Oprea TI (2002) Current trends in lead discovery: are we looking for the appropriate properties? J Comput-Aided Mol Des 16: 325–334.
|
| [33] | Schneider G (2002) Trends in virtual computational library design. Curr Med Chem 9: 2095–2102.
|
| [34] | Verdonk ML, Cole JC, Hartshorn ML, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609–623.
|
| [35] | Van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2: 192–204.
|
| [36] | Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, et al. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615–2623.
|
| [37] | Hedley PL, J？rgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, et al. (2009) The genetic basis of long QT and short QT syndromes: A mutation update. Human Mutation 30: 1486–1511.
|
| [38] | Vandenberg JI, Walker BD, Campbell TJ (2001) HERG K+ channels: Friend or foe. Trends Pharmacol Sci 22: 240–246.
|
| [39] | Chiesa N, Rosati B, Arcangeli A, Olivotto M, Wanke E (1997) A novel role for HERG K+ channels: spike-frequency adaptation. J Physiol 501: 313–318.
|
| [40] | Aronov AM (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov Today 10: 149–155.
|
| [41] | KhannaV, Ranganathan S (2011) Structural diversity of biologically interesting datasets: a scaffold analysis approach. J Cheminform 3: 30.
|
| [42] | Block S, Gerkens P, Peulen O, Jolois O, Mingeot-Leclercq MP, et al. (2005) Induction of apoptosis in Human promyelocytic leukemia cells by a natural trachylobane diterpene. Anticancer Res 25: 363–368.
|
| [43] | Hoet S, Stévigny C, Block S, Opperdoes F, Colson P, et al. (2004) Alkaloids from Cassytha filiformis and realted aporphines: antitrypanosomal activity, cytotoxicity, and interation with DNA and topoisomerases. Planta Med 70: 407–413.
|
| [44] | Okogun JI, Adesomoju AA, Adesida GA, Lindner HJ, Habermehl G (1982) Roseanolone: A new diterpene from Hypoestoes rosea. Z Naturforsch 37c: 558–561.
|
| [45] | Ojo-Amaize EA, Nchekwube EJ, Cottam HB, Bai R, Verdier-Pinard P, et al. (2002) Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action. Cancer Res 62: 4007–4014.
|
| [46] | Ojo-Amaize EA, Kapahi P, Kakkanaiah VN, Takahashi T, Shalom-Barak T, et al. (2001) Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IκB kinase. Cellular Immunology 209: 149–157.
|
| [47] | Salama MM, Kandil ZA, Islam WT (2012) Cytotoxic compounds from the leaves of Gaillardia aristata Pursh. growing in Egypt. Nat Prod Res 26 (22): 2057–2062.
|
| [48] | Jackson SJ, Houghton PJ, Retsas S, Photiou A (2000) In vitro cytotoxicity of norviburtinal and isopinnatal from Kigelia pinnata against cancer cell lines. Planta Med 66: 758–761.
|
| [49] | Schwikkard S, van Heerden RF (2002) Anti-malarial activity of plant metabolites. Nat Prod Rep 19(6): 675–692.
|
| [50] | Magadula JJ, Erasto P (2009) Bioactive natural products derived from the East African flora. Nat Prod Rep 26: 1535–1554.
|
| [51] | Titanji VPK, Zofou D, Ngemenya MN (2008) The anti-malarial potential of medicinal plants used for the treatment of malaria in Cameroonian Folk Medicine, Afr J Trad CAM. 5(3): 302–321.
|
| [52] | Kuete V, Efferth T (2010) Cameroonian medicinal plants: pharmacology and derived natural products. Frontiers in Pharmacology 1: 123.
|
| [53] | Ntie-Kang F, Lifongo LL, Mbaze LM, Ekwelle N, Owono Owono LC, et al. (2013) Cameroonian medicinal plants: a bioactivity versus ethnobotanical survey and chemotaxonomic classification. BMC Complement Altern Med 13(1): 147.
|
| [54] | Hoet S, Opperdoes F, Brun R, Quetin-Leclercq J (2004) Natural products active against African trypanosomes: a step towards new drugs. Nat Prod Rep 21: 253–264.
|
| [55] | Kuete V (2010) Potential of Cameroonian plants and derived products against microbial infections: a review. Planta Med 76: 1479–1491.
|
| [56] | Banzouzi JT, Prado R, Menan H, Valentin A, Roumestan C, et al. (2004) Studies on medicinal plants of Ivory Coast: Investigation of Sida acuta for in vitro antiplasmodial activities and identification of an active constituent. Phytomedicine 11: 338–341.
|
| [57] | Chibale K, Davies-Coleman M, Masimirembwa C (2012) Drug discovery in Africa: impacts of genomics, natural products, traditional medicines, insights into medicinal chemistry, and technology platforms in pursuit of new drugs. Springer.
|
| [58] | pan-ANAPL: pan-African Natural Products Library. Available: http://www.linkedin.com/groups/pANPL-409？8579/about/Accessed 2013 June 13.
|
| [59] | Mahmoudi N, De Julian-Ortiz JV, Ciceron L, Galvez J, Mazier D, et al. (2006) Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother 57: 489–497.
|
| [60] | Bickii J, Njifutie N, Foyere JA, Basco LK, Ringwald P (2000) In vitro antimalarial activity of limonoids from Khaya grandifoliola C.D.C. (Meliaceae). J Ethnopharmacol 69: 27–33.
|
| [61] | Chemical Computing Group Inc.: Molecular Operating Environment Software. Montreal; 2010.
|
| [62] | Halgren TA (1996) Merck molecular forcefield. J Comput Chem 17: 490–641.
|
| [63] | Schr？dinger: LigPrep software, version 2.5, LLC, New York, NY; 2011.
|
| [64] | Schr？dinger: Maestro, version 9.2, LLC, New York, NY; 2011.
|
| [65] | Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, et al. (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6: 1509–1519.
|
| [66] | Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118(45): 11225–11236.
|
| [67] | Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110(6): 1657–1666.
|
| [68] | Schr？dinger: QikProp, version 3.4, LLC, New York, NY, 2011.
|
| [69] | Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54: 355–366.
|
| [70] | Duffy EM, Jorgensen WL (2000) Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 122: 2878–2888.
|
| [71] | Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 10: 1155–1158.
|
| [72] | Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL (2001) Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 44: 4370–4378.
|
| [73] | Luco JM (1999) Prediction of brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modelling. J Chem Inf Comput Sci 39: 396–404.
|
| [74] | Kelder J, Grootenhuis PD, Bayada DM, Delbresine LP, Ploemen JP (1999) Polar molecular surface as a dominating determinant for oral absorption and brain pernetration of drugs. Pharm Res 16: 1514–1519.
|
| [75] | Ajay, Bermis GW, Murkco MA (1999) Designing libraries with CNS activity. J Med Chem 42: 4942–4951.
|
| [76] | Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15: 1490–1494.
|
| [77] | Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, et al. (1999) MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88: 28–33.
|
| [78] | Stenberg P, Norinder U, Luthman K, Artursson P (2001) Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44: 1927–1937.
|
| [79] | Cavalli A, Poluzzi E, De Ponti F, Recanatini M (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA Study of HERG K+ channel blockers. J Med Chem 45: 3844–3853.
|
| [80] | De Ponti F, Poluzzi E, Montanaro N (2001) Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 57: 185–209.
|
| [81] | Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9: 663–669.
|
| [82] | Potts RO, Guy RH (1995) A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity. Pharm Res 12: 1628–1633.
|
| [83] | ChemAxon: JChem software, version 5.11.3; 2012. Website. Available: https://www.chemaxon.com/jchem/doc/user/？LibMCS.html/Accessed 2013 June 13.
|
| [84] | Lewell XQ, Judd DB, Watson SP, Hann MM (1998) RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 38: 511–522.
|
| [85] | R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna; 2012. Website http://www.R-project.org/Accessed 2013 June 13.
|
